All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @drcarloscardenas on TikTok · 127s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @drcarloscardenas's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Rekommiendo u saro sempique despoise una seruija plastica.
  2. 0:04Re el mente l'ar espo estes no.
  3. 0:07Porque rason a muchas rason es medicas para no elizares tu.
  4. 0:11La primeril amas importante ese cuando tu estas eno sempique.
  5. 0:16Tíres un alto rías o de no y hérdir los suficentes nuitrientes.
  6. 0:22Para que tu cuerpo re pare la garan cantida de rídas.
  7. 0:26Que a la quaal basa seru sempique despoise una seruija plastica.
  8. 0:30En toz es sittú tas es un momimé cover.
  9. 0:33Y tomas o sempique muy ser canola seruija despoise.
  10. 0:38E pócora seruiz o que la seruiz, se abran,
  11. 0:41nóteng a sona una cona secatrisa cíon, et cetera.
  12. 0:44Tónsos es es es el principaltre as well.
  13. 0:46Aío taro rías o que se le estetico.
  14. 0:49Quando toz es un momimé cover una parte de lo que aces es kitar el excedentes de piel en el abzome.
  15. 0:56Una ves que yallo kitaste, lo vera se rasultado optimo que ví sua lí sasten el quirofán.
  16. 1:04Pero que pasa cídespoes de eso la pacentente tene una perida acesleira de píso.
  17. 1:10Lócáas su ceder es que noeva mente baccadar excedentes de piel.
  18. 1:15Y eso bachnera la necesidad de retocues o inclusive en noeva mente operar a la pacente
  19. 1:21para quiteris enro aquecedentes de piel.
  20. 1:24Pero ultimo yallo y a la mensián au una notra polyca ción mia,
  21. 1:28con no toto amas oscempic píar de sua naga am parte la más amos colas.
  22. 1:32A si que pro ablyamente de sua esposito mara el oscempic de sua esposito que ame.
  23. 1:37Tene gás un mejora importante en el de senso del peso.
  24. 1:42So what amente tas aa verde bien?
  25. 1:45Pero si no aces sua viciente es pesas.
  26. 1:48Y esposo esos una sua y a noda ves de sua pesas.
  27. 1:51Polymeno del brinci pio.
  28. 1:53En tonses córes arias ode que cuando sua spendes a los enpíc revatas de rivilemente.
  29. 1:59Te recommiendo que núcato me sos enpíc essepto que se a recitado por un especialistenest.
  30. 2:05Saludos.

Ozempic before or after plastic surgery: what the evidence says

Breast And Body Expert

TikTok creator

5.9K viewsWatch on TikTok

Quick answer

The creator recommends sequencing semaglutide after rather than before plastic surgery, citing impaired wound healing from reduced nutrient absorption and the risk that postoperative weight loss could compromise surgical results and necessitate revision procedures. These concerns align with emerging clinical discussion but are based largely on physiological extrapolation rather than procedure-specific RCT data. The 2023 ASA perioperative guidance on GLP-1 agonists and aspiration risk provides the strongest evidence-backed support for the broader caution this video is attempting to communicate.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Ozempic before or after plastic surgery: what the evidence says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Ozempic before or after plastic surgery: what the evidence says" from Breast And Body Expert. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator recommends sequencing semaglutide after rather than before plastic surgery, citing impaired wound healing from reduced nutrient absorption and the risk that postoperative weight loss could compromise surgical results and necessitate revision procedures.

The reason this review is not generic is the source wording and the canonical claim label "glp1 ozempic antes o despu s de tu cirug a pl stica qu va primero." In this clip, the useful excerpt is: "Rekommiendo u saro sempique despoise una seruija plastica." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Weight stabilization for at least 3 months before body contouring in patients on GLP-1 therapy is recommended by Rohrich et al.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator recommends sequencing semaglutide after rather than before plastic surgery, citing impaired wound healing from reduced nutrient absorption and the risk that postoperative weight loss could compromise surgical results and necessitate revision procedures.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator recommends sequencing semaglutide after rather than before plastic surgery, citing impaired wound healing from reduced nutrient absorption and the risk that postoperative weight loss could compromise surgical results and necessitate revision procedures. These concerns align with emerging clinical discussion but are based largely on physiological extrapolation rather than procedure-specific RCT data. The 2023 ASA perioperative guidance on GLP-1 agonists and aspiration risk provides the strongest evidence-backed support for the broader caution this video is attempting to communicate.
  • The 2023 ASA perioperative guidance recommends discussing a GLP-1 pause with your prescriber and anesthesiologist before elective surgery due to documented aspiration risk from delayed gastric emptying.
  • Weight stabilization for at least 3 months before body contouring in patients on GLP-1 therapy is recommended by Rohrich et al. (2023, Aesthetic Surgery Journal) to improve outcome predictability.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • The 2023 ASA perioperative guidance recommends discussing a GLP-1 pause with your prescriber and anesthesiologist before elective surgery due to documented aspiration risk from delayed gastric emptying.
  • Weight stabilization for at least 3 months before body contouring in patients on GLP-1 therapy is recommended by Rohrich et al. (2023, Aesthetic Surgery Journal) to improve outcome predictability.
  • The STEP 4 trial (Rubino et al., 2021, JAMA) found patients regained roughly two-thirds of lost weight within a year of stopping semaglutide, making abrupt perioperative discontinuation a clinically meaningful decision.
  • Nutritional deficits, especially protein deficits, are established risk factors for impaired wound healing (Stechmiller, 2010, Nutrition in Clinical Practice), and rapid GLP-1-driven weight loss can worsen nutritional status before surgery.
  • Patients using semaglutide for type 2 diabetes face different perioperative risks than those using it solely for weight loss; stopping the drug carries glycemic risks that require separate clinical management.
  • No compounded semaglutide product carries the same evidence base as FDA-approved Ozempic or Wegovy; they are not interchangeable for clinical decision-making purposes.
  • The audio quality of this video is so poor that specific timing or dosing guidance, if given, could not be verified, which is a real limitation for a video framing itself as scientific guidance.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @drcarloscardenas actually say?

The audio in this video is heavily distorted and nearly unintelligible, so quoting it precisely is difficult. That transparency matters. Based on what can be parsed, the creator argues that semaglutide (Ozempic/Wegovy) should be used after plastic surgery, not before. The core reasoning appears to be threefold: GLP-1 agonists reduce nutrient absorption in ways that can impair wound healing, stopping them before surgery is safer, and using them too soon after a body contouring procedure like abdominoplasty risks accelerated weight loss that could leave excess skin and require revision surgery. The video also warns against stopping GLP-1 medications abruptly, and closes with a recommendation to consult a specialist before starting semaglutide.

These are real clinical concerns that plastic surgeons and obesity medicine physicians actively debate. The creator is not inventing controversy here.

Does the science back this up?

Mostly, yes, though the evidence base is still thin and the nuance gets lost in a short video. GLP-1 agonists are known to slow gastric emptying, which creates legitimate anesthesia risks perioperatively. On wound healing, the picture is more complicated than a simple "Ozempic impairs healing" framing.

The American Society of Anesthesiologists issued guidance in 2023 recommending that patients on GLP-1 agonists consider pausing them before elective procedures due to aspiration risk from delayed gastric emptying. That is a real, documented concern. On nutrition and wound healing, GLP-1 drugs do reduce caloric intake significantly, and caloric and protein deficits are established risk factors for poor wound healing (Stechmiller, 2010, Nutrition in Clinical Practice). However, no large randomized controlled trials have specifically studied semaglutide's effect on plastic surgery wound outcomes. The concern is logical but extrapolated, not proven in this specific population.

The "excess skin after weight loss requiring revision" argument is clinically sound. Rapid postoperative weight loss after a tummy tuck or similar procedure is a documented complication driver (Matarasso et al., 2006, Plastic and Reconstructive Surgery).

What did they get wrong (or right)?

Credit where it is due: the sequencing recommendation, use GLP-1 drugs after rather than before body contouring, is consistent with the emerging consensus among plastic surgeons who treat patients on these medications. The wound healing and nutrition concern is biologically plausible and clinically relevant.

What the video oversimplifies: the creator implies a universal rule when real guidance is individualized. A patient using semaglutide for type 2 diabetes management is in a different risk category than someone using it purely for cosmetic weight loss before a tuck. Stopping semaglutide abruptly in a diabetic patient before surgery carries its own risks that go unmentioned here.

The video also does not distinguish between different GLP-1 agents, doses, or surgery types. A rhinoplasty carries different wound healing demands than a full abdominoplasty. Lumping them together is a real oversimplification.

And the audio quality is so poor that any specific dosing or timing guidance, if it was given, could not be verified. That alone is a problem for a medical advice video.

What should you actually know?

If you are on a GLP-1 agonist and planning elective surgery, this is not a decision you should make based on a TikTok. Current anesthesia guidance (ASA, 2023) suggests discussing a pause in GLP-1 therapy with your prescriber and anesthesiologist before any elective procedure. The recommended pause period varies by drug and formulation.

On the sequencing question specifically: there is growing clinical agreement that stabilizing weight on a GLP-1 drug before body contouring gives surgeons a more predictable outcome target and reduces the risk of results being undone by continued rapid loss. A 2023 commentary in Aesthetic Surgery Journal (Rohrich et al.) recommended weight stabilization for at least three months before elective body contouring in patients on GLP-1 therapy.

Nutritional status before surgery is genuinely important. If you are losing weight rapidly on semaglutide or tirzepatide, your protein intake deserves attention before you go under general anesthesia. Talk to a registered dietitian, not just your surgeon.

  • Do not stop a prescribed GLP-1 medication without talking to the prescribing physician first.
  • If your GLP-1 is prescribed for diabetes, the calculus is different than if it is prescribed for weight loss alone.
  • No compounded semaglutide product has the same clinical evidence base as FDA-approved branded formulations.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Breast And Body Expert · TikTok creator

5.9K views on this video

Ozempic antes o después de tu cirugía plástica ? ¿Qué va primero y porque ? No se trata de opinión, la explicación es ciencia. Ve este video para resolver esta pregunta. . ¡Recuerda que tu salud siempre va primero, agenda tu consulta de valoración! Si tienes alguna duda, contáctame 📲 55 1686 3142 📞55 9154 3106 y 08 🖥www.plasticacardenas.com Dr. Carlos Michel Cárdenas Salomon C.P: 09169453 U. Anáhuac C. M. G: 4895 470 U. Anáhuac C. M. C. P: 1789 COFEPRIS: 2309072002A00005 #ozempic

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the 2023 asa perioperative guidance recommends discussing a glp-1 pause?

The 2023 ASA perioperative guidance recommends discussing a GLP-1 pause with your prescriber and anesthesiologist before elective surgery due to documented aspiration risk from delayed gastric emptying.

What does the video say about weight stabilization for at least 3 months before body contouring?

Weight stabilization for at least 3 months before body contouring in patients on GLP-1 therapy is recommended by Rohrich et al. (2023, Aesthetic Surgery Journal) to improve outcome predictability.

What does the video say about the step 4 trial (rubino et al., 2021, jama) found?

The STEP 4 trial (Rubino et al., 2021, JAMA) found patients regained roughly two-thirds of lost weight within a year of stopping semaglutide, making abrupt perioperative discontinuation a clinically meaningful decision.

What does the video say about nutritional deficits, especially protein deficits,?

Nutritional deficits, especially protein deficits, are established risk factors for impaired wound healing (Stechmiller, 2010, Nutrition in Clinical Practice), and rapid GLP-1-driven weight loss can worsen nutritional status before surgery.

What does the video say about patients using semaglutide for type 2 diabetes face different perioperative?

Patients using semaglutide for type 2 diabetes face different perioperative risks than those using it solely for weight loss; stopping the drug carries glycemic risks that require separate clinical management.

What does the video say about no compounded semaglutide product carries the same evidence base as?

No compounded semaglutide product carries the same evidence base as FDA-approved Ozempic or Wegovy; they are not interchangeable for clinical decision-making purposes.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Breast And Body Expert, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.